Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Oncology
Second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT).
Hematology December 21st 2021